Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia

Metabolism: Clinical and Experimental

Volumn 56, Issue 11, 2007, Pages 1534-1541

  Arca, Marcello ^a   Montali, Anna ^a   Pigna, Giovanni ^a   Antonini, Roberto ^a   Antonini, Teresa Maria ^a   Luigi, Petramala ^a   Fraioli, Antonio ^a   Mastrantoni, Marco ^b   Maddaloni, Maura ^b   Letizia, Claudio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; APOLIPOPROTEIN B; ATORVASTATIN; ENDOTHELIN 1; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERLIPEMIA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROCETOFEN; PYRROLES;

EID: 35248884433     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.06.021     Document Type: Article

References (43)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 (1973) 1544-1568
2. Gaddi A., Galletti C., Pauciullo P., et al. Familial combined hyperlipoproteinemia: experts panel position on diagnostic criteria for clinical practice. Committee of Experts of the Atherosclerosis and Dysmetabolic Disorders Study Group. Nutr Metab Cardiovasc Dis 9 (1999) 304-311
3. Sniderman A.D., Ribalta J., and Castro Cabezas M. How should FCHL be defined and how should we think about its metabolic bases?. Nutr Metab Cardiovasc Dis 11 (2001) 259-273
4. Ayyobi A.F., McGladdery S.H., McNeely M.J., et al. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23 (2003) 1289-1294
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-9247
6. Vicari R.N., Wan G.J., Aura A.M., et al. Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. Arch Fam Med 9 (2000) 898-905
7. Staels B., Dallongeville J., Auwerx K., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
8. Shek A., and Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother 35 (2001) 908-917
9. Jones P.H., Davidson M.H., Stein E.A., et al., for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 92 (2003) 152-160
10. Stein D.T., Devaraj S., Balis D., et al. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21 (2001) 2026-2031
11. Kovacs I., Toldy E., Abel T., et al. The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia. Endothelium 12 (2005) 179-183
12. Sebestjen M., Zegura B., Videcnik V., et al. Determinants of endothelial dysfunction and carotid intima-media thickness in combined hyperlipidemia. Coron Artery Dis 16 (2005) 175-180
13. Stroes E., de Bruin T., de Valk H., et al. NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants. Cardiovasc Res 36 (1997) 445-452
14. Sudano I., Spieker L.E., Hermann F., et al. Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol 47 Suppl 2 (2006) S136-S150
15. Kato J., Tsuruda T., Kita T., et al. Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 25 (2005) 2480-2487
16. Kawai J., Ando K., Tojo A., et al. Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation 109 (2004) 1147-1153
17. Porkka K.V., Nuotio I., Pajukanta P., et al. Phenotype expression in familial combined hyperlipidemia. Atherosclerosis 133 (1997) 245-253
18. Campagna F., Montali A., Baroni M.G., et al. Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the beta3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. Metabolism 51 (2002) 1298-1305
19. Veerkamp M.J., Graaf deJ., Hendriks J.C., et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 109 (2004) 2980-2985
20. Lowry O., Rosebrough N., Farr A., et al. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
21. Campos H., Blijlevens E., McNamara J.R., et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb 12 (1992) 1410-1419
22. Letizia C., Cerci S., Centanni M., et al. Circulating levels of adrenomedullin in patients with Addison's disease before and after corticosteroid treatment. Clin Endocrinol (Oxf) 48 (1998) 145-148
23. Letizia C., Cerci S., De Ciocchis A., et al. Plasma endothelin-1 levels in normotensive and borderline hypertensive subjects during a standard cold pressor test. J Hum Hypertens 9 (1995) 903-907
24. Bairaktari E.T., Tzallas C.S., Tsimihodimos V.K., et al. Comparison of efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 6 (1999) 113-116
25. Frost R.J.A., Otto C., Geiss H.C., et al. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87 (2001) 44-48
26. Despres J.P., Lemieux I., Salomon H., et al. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J Int Med 251 (2002) 490-499
27. Melenovsky V., Malik J., MD, Wichterle D., et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 144 (2002) e6
28. Versyden C., Meijssen S., and Cabezas M.C. Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 89 (2004) 5972-5980
29. Bilz S., Wagner S., Schmitz M., et al. Effects of atorvastatin versus fenofibrate on apoB-100 and apo A-I kinetics in mixed hyperlipidemia. J Lipid Res 45 (2004) 174-185
30. Gaw A., Packard C.J., Murray E.F., et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb 13 (1993) 170-189
31. Geiss H.C., Otto C., Schawandt P., et al. Effect of atorvastatin on low-density lipoprotein subtype in patients with different form of hyperlipoproteinemia and control subjects. Metabolism 50 (2001) 983-989
32. Otvos J.D., Shalaurova I., Freedman D.S., et al. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-1 trial. Atherosclerosis 160 (2002) 41-48
33. Pontreli L., Parris W., Adeli K., et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 51 (2002) 334-342
34. Guerin M., Lassel T.S., Le Goff W., et al. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
35. Thompson G.R., and Barter P.J. Clinical lipidology at the end of the millennium. Curr Opin Lipidol 10 (1999) 521-526
36. Barter P., Kastelein J., Nunn A., Hobbs R., and and the Future Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis: the unanswered questions. Atherosclerosis 168 (2003) 195-211
37. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992) 37-45
38. Grundy S.M. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am J Cardiol 75 (1995) 45B-52B
39. Dean B.B., Borenstein J.E., Henning J.M., et al. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?. Am Heart J 147 (2004) 966-976
40. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
41. Economides P.A., Caselli A., Tiani E., et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 740-747
42. Tsung-Ming L., Sheng-Fang S., and Chang-Her T. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40 (2002) 67-73
43. Huang Y., Dai G., Feng Z., Lu C., et al. Effects of micronized fenofibrate on vascular endothelial function in patients with hypertriglyceridemia. Chin Med J 116 (2003) 1767-1769